2-(1-{6-[(2-[F-18]Fluoroethyl) (Methyl)Amino]-2-naphthyl} Ethylidene) Malononitrile-PET for in Vivo Diagnose of Tauopathy in Unclassified Parkinsonism

Inclusion Criteria: * The subject is male or female ≥ 40 years old; * The individual has one of these three conditions: * probable PSP according to criteria of the National Institute of Neurological Disorders and Stroke (NINDS) * probable MSA according to criteria of the Second consensus statement on the diagnosis of multiple system atrophy * unclassifiable parkinsonism according to criteria defined by Katzenschlager et al, 2003: * Patients with atypical parkinsonism without response to treatment with levodopa and does not meet any of the diagnostic criteria for other known atypical parkinsonism * Patient given written consent Exclusion Criteria: * The subject is diagnosed with Parkinson's Disease and meets the diagnostic criteria United Kingdom Parkinson's Disease Society Brain Bank -The subject is pregnant or breastfeeding; * The subject has a history of drug abuse or alcohol; * The subject has a moderate or severe renal function impairment (creatinine serum\> 1.5 mg / dL); * The subject has a moderate or severe hepatic impairment (bilirubin\> 2 times the upper limit of normal, transaminases\> 3 times the limit top of normal); * The subject presents structural abnormalities in the basal ganglia or cortical level on MRI or CT; * The subject has participated in a clinical study with a pharmaceutical product investigation within 30 days prior to screening and / or a radiopharmaceutical minimum period of 5 radioactive half-lives prior to screening; * Occupational exposure to radiation\> 15 milliSievert (mSv) / year * Use of nonsteroidal antiinflammatory drug (NSAIDs), for some reason, can not be replaced by any other drug 4 weeks before the PET scan; * The subject has allergy investigational product or any of its components; * The subject has a clinically severe active disease, with a hope reduced life; * The subject is claustrophobic / a.